Recent Quotes (30 days)

You have no recent quotes
chg | %

Cardiovascular Systems Inc  

(Public, NASDAQ:CSII)   Watch this stock  
Find more results for CSII
25.33
+0.57 (2.30%)
After Hours: 25.33 0.00 (0.00%)
Jan. 16, 4:29p.m. EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.57 - 25.47
52 week 23.00 - 33.11
Open 24.93
Vol / Avg. 225,181.00/225,838.00
Mkt cap 838.05M
P/E     -
Div/yield     -
EPS -0.06
Shares 34.14M
Beta 2.52
Inst. own 78%
Feb. 7, 2018
Q2 2018 Cardiovascular Systems Inc Earnings Call - 4:45p.m. EST - Add to calendar
Feb. 7, 2018
Q2 2018 Cardiovascular Systems Inc Earnings Release - 4:00p.m. EST - Add to calendar
Nov. 16, 2017
Cardiovascular Systems Inc Annual Shareholders Meeting (Estimated)
Nov. 15, 2017
Cardiovascular Systems Inc Annual Shareholders Meeting - Webcast
Oct. 25, 2017
Q1 2018 Cardiovascular Systems Inc Earnings Call - Webcast
Oct. 25, 2017
Q1 2018 Cardiovascular Systems Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep. '17) 2017
Net profit margin -3.98% -0.87%
Operating margin -3.53% -0.75%
EBITD margin - 1.27%
Return on average assets -4.13% -1.07%
Return on average equity -6.65% -1.63%
Employees 579 -
CDP Score - -

Address

1225 Old Highway 8 NW
ST. PAUL, MN 55112-6416
United States - Map
+1-651-2591600 (Phone)
+1-612-6773355 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Officers and directors

Scott R. Ward Chairman of the Board, President, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Laurence L. Betterley Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Sandra Sedo Chief Compliance Officer
Age: 53
Bio & Compensation  - Reuters
Alexander Rosenstein General Counsel and Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Laura Gillund Chief Talent Officer
Age: 56
Bio & Compensation  - Reuters
Martha Goldberg Aronson Independent Director
Age: 50
Bio & Compensation  - Reuters
Scott A. Bartos Independent Director
Age: 54
Bio & Compensation  - Reuters
Brent G. Blackey Independent Director
Age: 58
Bio & Compensation  - Reuters
Edward M. Brown Independent Director
Age: 54
Bio & Compensation  - Reuters
William E. Cohn M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters